Vanguard Group Inc Aptinyx Inc. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.12 - $0.69 $5,422 - $31,181	45,191 Added 2.49%	1,860,971 $223,000
Q4 2022 Feb 10, 2023	BUY	$0.23 - $0.34 $191 - $282	832 Added 0.05%	1,815,780 $526,000
Q3 2022 Nov 14, 2022	SELL	$0.35 - $0.72 $52,188 - $107,359	-149,110 Reduced 7.59%	1,814,948 $668,000
Q1 2022 May 13, 2022	BUY	$2.27 - $3.62 $347,180 - $553,653	152,943 Added 8.44%	1,964,058 $4.46 Million
Q4 2021 Feb 14, 2022	SELL	$2.11 - $3.0 $2,335 - $3,321	-1,107 Reduced 0.06%	1,811,115 $4.84 Million
Q3 2021 Nov 12, 2021	BUY	$2.21 - $2.89 $8,177 - $10,693	3,700 Added 0.2%	1,812,222 $4.24 Million
Q2 2021 Aug 13, 2021	BUY	$2.39 - $3.5 $4.32 Million - $6.33 Million	1,808,522 New	1,808,522 $5.12 Million

Ticker APTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,715,696
Description
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.